Qure.ai and Therapixel have announced a new partnership whereby Qure.ai will be a global distributor for Therapixel’s MammoScreen. Photo courtesy Therapixel-Mammoscreen.
March 2, 2023 — Qure.ai, a London-based medical Artificial Intelligence (AI) imaging company, has announced a new partnership with Therapixel, a French firm that uses AI to improve the early breast cancer detection, whereby Qure.ai will be a global distributor for Therapixel’s MammoScreen. In a statement issued by Qure.ai, through the partnership, Qure.ai and Therapixel aim to improve the accuracy and efficiency of breast cancer detection, by enabling radiologists to read large numbers of screening mammograms in 2D and 3D more confidently.
According to recent studies, as noted in a statement issued on the partnership, MammoScreen enabled radiologists of all experience levels to significantly improve their performance regarding the number of cancers detected and reading time. As a result, noted the company statement, the partnership between Qure.ai and Therapixel will benefit healthcare providers and patients globally with more accurate and efficient detection of breast cancer, ultimately leading to earlier diagnosis and better outcomes.
“Qure.ai is breaking new ground by bringing a fellow radiology AI provider on board for the first time in our history,” said Prashant Warier, CEO and Co-Founder of Qure.ai. Warier noted the collaboration builds on the company’s global distribution networks, opening a pipeline for future partnerships.
Matthieu Leclerc-Chalvet, CEO of Therapixel, added, “We are excited to partner with Qure.ai and expand the reach of MammoScreen across the globe,” said Matthieu Leclerc-Chalvet, CEO of Therapixel.
The update also noted that both less experienced and expert radiologists can achieve a high detection rate and improve their reading time with MammoScreen. Qure.ai offers a comprehensive imaging AI portfolio globally, covering lung and breast cancer, among other disease areas. The portfolio now also covers abnormality detection across Chest X-rays, Chest CTs, Head CTs, Musculoskeletal X-rays, and Breast Mammograms, allowing these cutting-edge AI solutions assist radiologists in faster and earlier diagnosis across different healthcare workflows and geographies.
Qure.ai recently announced (see related coverage below) it has been awarded CE Class IIb certification for medical devices under the European Union Medical Device Regulation (Regulation (EU) 2017/745) (EU-MDR).
The companies will be participating in the 2023 European Congress of Radiology (ECR) being held March 1-5 in Vienna, Austria. For its part, qure.ai reports that the company launched an AI playbook with CaritasKlinikum Saarbrücken, to provide European clinicians and radiologists with a helpful guide to understanding the business case for AI in radiology. Additionally, the company hosted a panel discussion, “AI Sparking the Cycle of Change” during the global conference.
For more information:
Related content:
May 04, 2026 
